Opendata, web and dolomites

EURE-CART SIGNED

EURopean Endeavour for Chimeric Antigen Receptor Therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EURE-CART project word cloud

Explore the words cloud of the EURE-CART project. It provides you a very rough idea of what is the project "EURE-CART" about.

demonstrated    successful    extend    personalised    smes    tumour    conducting    regulatory    car    track    trial    secondary    respective    adoptive    stage    gene    anti    academic    unparalleled    struggles    industry    chronic    representing    enormously    leaders    reactive    constrains    meet    uniquely    therapeutic    ultimate    bodies    proposes    defeating    secure    experts    molmed    unprecedented    tumours    expensive    countries    enterprise    tackled    record    establishment    centralisation    causing    pioneers    oncology    diseases    chimeric    though    billions    jobs    first    cells    man    innovative    genetically    accelerating    therapies    cart    academia    eur    excellences    applicability    approval    cell    frequent    clinical    incurable    death    instalment    forefront    never    cancer    eradicate    antigen    immunotherapy    causes    receptor    national    involvement    centres    therapy    endowed    alliance    eure    spa    modified    create   

Project "EURE-CART" data sheet

The following table provides information about the project.

Coordinator
MOLECULAR MEDICINE SPA 

Organization address
address: VIA OLGETTINA 58
city: MILANO
postcode: 20132
website: www.molmed.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://www.eure-cart.eu/
 Total cost 5˙903˙146 €
 EC max contribution 5˙903˙146 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MOLECULAR MEDICINE SPA IT (MILANO) coordinator 1˙994˙575.00
2    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 1˙112˙500.00
3    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 856˙076.00
4    OSPEDALE PEDIATRICO BAMBINO GESU IT (ROMA) participant 492˙431.00
5    ACROMION GMBH DE (FRECHEN) participant 398˙000.00
6    ARTTIC FR (PARIS) participant 375˙000.00
7    FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU ES (BARCELONA) participant 225˙011.00
8    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 225˙000.00
9    FAKULTNI NEMOCNICE OSTRAVA CZ (OSTRAVA PORUBA) participant 224˙552.00

Map

 Project objective

Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing secondary chronic diseases. This approach is already at an advanced stage of development in the US, but struggles in the EU, due to a number of constrains that will be specifically tackled by this Project. The ultimate goal of EURE-CART is to bring EU at the forefront CAR T-cell immunotherapy. In this Project, we will extend the applicability of CAR T-cell immunotherapy to incurable tumours that have never been tackled with this approach. The EURE-CART Consortium is composed of 6 academic centres, 2 SMEs and 1 large enterprise from 6 EU countries, clearly representing excellences in their respective fields. EURE-CART will bring together clinical experts in oncology, and pioneers and leaders in the field of cell and gene therapy for conducting a first-in-man Phase I/II clinical trial. To be successful, EURE-CART proposes the early involvement of National regulatory authorities for accelerating the approval of CAR T-cell immunotherapy, as well as the centralisation of its production by the Molmed Spa. Molmed Spa is uniquely endowed in the EU with the know-how and experience necessary to meet this ambitious objective, as demonstrated by its unparalleled track record. The main expected impact of EURE-CART is the establishment of CAR T-cell therapy as the ultimate personalised therapy, capable of defeating chronic diseases, and to create secure new jobs in the EU through the instalment of an unprecedented alliance between academia, industry and regulatory bodies.

 Deliverables

List of deliverables.
Preparation of a project logo and flyer Websites, patent fillings, videos etc. 2019-05-31 16:44:17
Individualised press releases Websites, patent fillings, videos etc. 2019-05-31 17:41:12
Signing-up of dedicated Twitter and LinkedIn accounts Websites, patent fillings, videos etc. 2019-05-31 17:41:08
Launch of dedicated website Websites, patent fillings, videos etc. 2019-05-31 16:44:21

Take a look to the deliverables list in detail:  detailed list of EURE-CART deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 \"\"\"F. Moretti, F. Capone, C. Traversari, M.C. Galli\"
Il Progetto europeo EURE-CART: l\'ISS tra i partner del nuovo approccio terapeutico e personalizzato per sconfiggere le malattie neoplastiche
published pages: 3-5, ISSN: 1827-6296, DOI:
Notiziario Istituto Superiore Sanità 31(11) 2020-03-05
2018 Franco Locatelli, Concetta Quintarelli
The EURE-CART project as a prototype model for CAR T-cell immunotherapy in Europe
published pages: 216-219, ISSN: 0014-2980, DOI: 10.1002/eji.201870029
European Journal of Immunology 48/2 2019-06-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EURE-CART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EURE-CART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More